A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i> <i>-</i> Altered Advanced Solid Tumor Malignancies (NCI 10170)
Edward Maldonado(University of California, San Francisco), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center)
Cited by 12
Related Papers
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
|European Urology|2017|218
Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
|Cancer Research|2022|58
<sup>68</sup>Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with<sup>18</sup>F-FDG
|Journal of Nuclear Medicine|2024|36
Initial Experience with<sup>68</sup>Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer
|Journal of Nuclear Medicine|2024|26
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
|Prostate Cancer and Prostatic Diseases|2024|9